Cargando…
Immunotherapies for advanced hepatocellular carcinoma
Primary liver cancer is the second leading cause of tumor-related deaths in China, with hepatocellular carcinoma (HCC) accounting for 80%–90% of these. Since there is a lack of symptoms in the early stages of HCC, a large proportion of patients were identified with unresectable HCC when diagnosed. D...
Autores principales: | Sun, Li-Yang, Zhang, Kang-Jun, Xie, Ya-Ming, Liu, Jun-Wei, Xiao, Zun-Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070708/ https://www.ncbi.nlm.nih.gov/pubmed/37025485 http://dx.doi.org/10.3389/fphar.2023.1138493 |
Ejemplares similares
-
Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies
por: Li, SiNi, et al.
Publicado: (2021) -
Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Hou, Jing-Yu, et al.
Publicado: (2022) -
Recent Advances in Nanotechnology for Dendritic Cell-Based Immunotherapy
por: Qian, Chen, et al.
Publicado: (2020) -
A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model
por: Wei, Yuhua, et al.
Publicado: (2022) -
Integrating machine learning to construct aberrant alternative splicing event related classifiers to predict prognosis and immunotherapy response in patients with hepatocellular carcinoma
por: Liu, Wangrui, et al.
Publicado: (2022)